We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$16.2B
AUM Growth
-$2.57B
Cap. Flow
+$150M
Cap. Flow %
0.93%
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$49.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$43.3M
3
KOD icon
Kodiak Sciences
KOD
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$27.5M
5
ALLK
Allakos
ALLK
+$27.1M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$60M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$48.2M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$10.4M
4
QURE icon
uniQure
QURE
+$9.23M
5
NXTC icon
NextCure
NXTC
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
26
Axsome Therapeutics
AXSM
$11.8B
$52.3M 0.32%
889,757
+60,000
+7% +$4.89M
INSM icon
27
Insmed
INSM
$22.5B
$48.5M 0.3%
3,025,384
+580,119
+24% +$13.8M
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$6.12B
$43.3M 0.27%
2,799,577
– –
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.35B
$41.2M 0.25%
2,708,200
– –
KRYS icon
30
Krystal Biotech
KRYS
$10.6B
$40.9M 0.25%
946,471
-88,203
-9% -$4.61M
NGNE icon
31
Neurogene
NGNE
$648M
$38.7M 0.24%
169,887
– –
CCXI
32
DELISTED
ChemoCentryx, Inc.
CCXI
$34.5M 0.21%
859,015
+119,999
+16% +$5.1M
ALLK
33
DELISTED
Allakos
ALLK
$32.7M 0.2%
735,469
+395,779
+117% +$27.1M
GWPH
34
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$32.5M 0.2%
370,845
– –
AUPH icon
35
Aurinia Pharmaceuticals
AUPH
$1.92B
$24.7M 0.15%
1,701,929
– –
MRUS
36
DELISTED
Merus
MRUS
$24.7M 0.15%
2,037,469
– –
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
$24M 0.15%
896,551
+399,582
+80% +$14.2M
ASMB icon
38
Assembly Biosciences
ASMB
$494M
$22.9M 0.14%
128,468
– –
BCRX icon
39
BioCryst Pharmaceuticals
BCRX
$2.43B
$21.9M 0.13%
10,946,166
– –
KRRO icon
40
Korro Bio
KRRO
$146M
$21M 0.13%
23,603
-1,026
-4% -$1.11M
ADPT icon
41
Adaptive Biotechnologies
ADPT
$3.51B
$20.7M 0.13%
743,734
-371,677
-33% -$10.4M
ALKS icon
42
Alkermes
ALKS
$8.08B
$17.9M 0.11%
1,244,744
+451,614
+57% +$8.06M
QURE icon
43
uniQure
QURE
$2.76B
$16.9M 0.1%
357,083
-160,617
-31% -$9.23M
XNCR icon
44
Xencor
XNCR
$1.45B
$12.8M 0.08%
428,120
– –
URGN icon
45
UroGen Pharma
URGN
$1.97B
$12M 0.07%
672,912
-158,576
-19% -$4.28M
PTGX icon
46
Protagonist Therapeutics
PTGX
$8.58B
$11.9M 0.07%
1,679,164
+504,882
+43% +$3.78M
ADAP
47
DELISTED
Adaptimmune Therapeutics
ADAP
$10M 0.06%
+3,690,307
New +$12.2M
AIMT
48
DELISTED
Aimmune Therapeutics
AIMT
$9.72M 0.06%
673,908
– –
UROV
49
DELISTED
Urovant Sciences Ltd.
UROV
$9.22M 0.06%
1,000,000
– –
MIRM icon
50
Mirum Pharmaceuticals
MIRM
$6.59B
$8.17M 0.05%
583,333
+250,000
+75% +$4.1M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Baker Bros. Advisors held 116 positions worth $16.2B, down 14% from $18.8B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2020 filing shows 17 new, 25 increased, 19 reduced and 6 closed positions. Its largest new stake was Adaptimmune Therapeutics: 3,690,307 shares worth $10M. The largest sale was Exact Sciences, an estimated $60M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2020 buy was Adaptimmune Therapeutics: 3,690,307 shares worth $10M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q1 2020, an estimated $49.3M increase.
  • Baker Bros. Advisors's biggest Q1 2020 reduction was Exact Sciences, cutting an estimated $60M.
  • Baker Bros. Advisors fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $48.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $16.2B portfolio in Q1 2020.
  • Baker Bros. Advisors opened 17 new positions and closed 6 in Q1 2020.
  • Baker Bros. Advisors's portfolio value fell 14% quarter-over-quarter to $16.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.